| Ytd | -45.60% | |
| 1y | -49.85% |
| Open | 6.66 | Prev Close | 6.66 | Low | 6.51 | High | 6.66 | Mkt Cap | 124.98M |
| Vol | 21.55K | Avg Vol | 445.31K | EPS | 1.09 | P/E | 6.11 | Forward P/E | 9.86 |
| Beta | 1.08 | Short Ratio | 2.70 | Inst. Own | 68.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.53 | 200-d Avg | 10.20 | 1yr Est | 10.36 |
OPRX News
OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology
OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life s
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and low
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.0
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst conse
OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the
OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 f
Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the
B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lo
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst conse
The newly executed agreements include:An exclusive, multi-year agreement with a high-demand e-prescr
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform
OptimizeRx (NASDAQ:OPRX) sees FY2026 sales of $118.000 million-$124.000 million vs $118.125 million
OptimizeRx (NASDAQ:OPRX) raises FY2025 sales outlook from $104.000 million-$108.000 million to $105.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
Friday's session saw 466 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Friday